A case of antisynthetase syndrome in a rheumatoid arthritis patient with anti-PL-12 antibody following treatment with etanercept.

• 石川, 優樹

• 湯川, 尚一郎

• Kawabata, Daisuke

• Ohmura, Koichiro

• Fujii, Takao

• Usui, Takashi

• Mimori, Tsuneyo

抄録

In our earlier study, we had reported the case of a patient with rheumatoid arthritis (RA), who had anti-Jo-1 antibodies. This patient had received etanercept (ETN) therapy for RA, after which she had developed overt polymyositis (PM). Although various autoimmune phenomena, including lupus-like diseases, vasculitides, or psoriatic skin lesions, are associated with antitumor necrosis factor (TNF) therapy, the development of PM/dermatomyositis (DM) or antisynthetase syndrome following anti-TNF therapy is extremely rare. Here, we report a case of an RA patient with anti-PL-12 antibodies, who received ETN therapy and subsequently developed the antisynthetase syndrome. She recovered when ETN therapy was withdrawn and high-dose corticosteroid was administered. To date, there have been only five reported cases of RA patients with anti-Jo-1 antibodies who developed overt PM/DM following anti-TNF therapy and only one case of antisynthetase syndrome in an RA patient with anti-PL-7 antibodies. Our patients and the abovementioned reports strongly suggest that onset of overt PM/DM or antisynthetase syndrome in RA patients with anti-aminoacyl tRNA synthetase antibodies is associated with anti-TNF therapy.

収録刊行物

• Clinical rheumatology

  Clinical rheumatology 30 (3), 429-432, 2011-03

  Springer Verlag

キーワード

• Adverse drug effect
• Anti-ARS antibodies
• Anti-TNF therapy
• Polymyositis/dermatomyositis

詳細情報

• CRID: 1050282677042645248
• NII論文ID: 120003039177
• NII書誌ID: AA10623843
• ISSN: 07703198
• HANDLE: 2433/141341
• 本文言語コード: en
• 資料種別: journal article
• データソース種別:
  • IRDB
  • CiNii Articles